Edward T. H. Yeh, M.D., FACC
Chairman, Department of Internal Medicine
Nolan Family Distinguished Chair in Internal Medicine
Dr. Yeh graduated from the University of California, Berkeley with a major in Biochemistry and received his medical degree from the University of California, Davis. He completed medical residency at the Boston VA Medical Center and did a post-doctoral fellowship in the laboratory of Nobel Laureate Baruj Benacerraf at Harvard Medical School. In 1987, he was appointed Assistant Professor of Medicine at the Massachusetts General Hospital and Harvard Medical School. In the early 1990’s, Dr. Yeh relocated to Houston to join the faculty of The University of Texas and the Texas Heart Institute. In 2000, he founded the Department of Cardiology at The University of Texas MD Anderson Cancer Center and developed a new field called Onco-cardiology that specializes on caring cancer patients who developed heart problems caused by cancer therapy. He was recruited to the University of Missouri at Columbia as Chair of the Department of Medicine and Director of the Center for Precision Medicine in 2016. In three years, he raised the department’s national ranking in NIH-funded research from 98 to 76. In 2020, he was appointed Chairman of the Department of Internal Medicine at the University of Arkansas for Medical Sciences and Nolan Family Distinguished Chair in Internal Medicine.
Dr. Yeh’s laboratory discovered Sentrin/SUMO that have revolutionized our understanding of cancer, heart disease, and neurodegenerative disorders. His laboratory also discovered the molecular basis of anthracycline-induced cardiotoxicity that shepherds in a new era of personalized cardio-protection for cancer patients undergoing chemotherapy. He received grants from the National Institute of Health, Department of Defense, and Cancer Prevention Research Institute of Texas. He was the McNair Scholar in the Texas Heart Institute, the Massachusetts General Hospital/Upjohn Scholar, Arthritis Investigator from the Arthritis Foundation, and the Established Investigator of the American Heart Association. Ed has mentored a large number of physician/scientists and basic scientists, who have become chair, dean, or independent investigators. He has written over 150 scientific papers, many of which are landmark contributions to science and medicine.
Dr. Yeh was elected to memberships in American Association of the Advancement of Science, the Association of American Physicians, American Society for Clinical Investigation, and Academia Sinica. He was honored as the Distinguished Alumnus of the University of California, Davis Medical School. He has held prominent positions as the President of the Houston Cardiology Society, President of the Board of American Heart Association, Houston Chapter, and board member of the American Heart Association, Texas and South-Central Affiliate.
Hui-Ming Chang, M.D., MPH
Professor of Pharmacology, Toxicology and Internal Medicine
About Dr. Chang
Dr. Hui-Ming Chang joined UAMS on November 1, 2020 as Professor of Pharmacology, Toxicology and Internal Medicine. Dr. Chang is a cross-discipline physician scientist with academic leadership experience in research, administration, education, and clinical medicine. She received her medical degree from National Taiwan University, master of public health in Epidemiology and master of science in Physiology from Harvard Chan School of Public Health. Her post-graduate trainings include internship at George Washington University Medical Center, residency at Boston University Medical Center, and clinical and research fellowship at Harvard Medical School, Boston Children’s Hospital. Dr. Chang comes to UAMS from University of Missouri School of Medicine where she was co-director of the Center for Precision Medicine and associate professor. Prior to U. of Missouri, she was faculty at Harvard Medical School, Massachusetts General Hospital, U. of Texas MD Anderson Cancer Center, and U. of Texas Health Science Center at Houston. Her prior academic positions include vice president for international programs and special advisor to the president at the U. of Texas Health Science Center at Houston, director of senior clinical performance examination at U. of Texas Houston Medical School, and director of education, Department of Palliative Care and Rehabilitation at U. of Texas MD Anderson Cancer Center.
Her services on national and institutional committees include Board of Directors of the American Academy of Pain Medicine, Executive Council of the University of Texas Health Science Center at Houston, and scientific advisory committee of the university clinical research center at the U. of Texas Health Science Center at Houston and MD Anderson Cancer Center. She was the recipient of Fleming and Davenport award and medical honoree of American Heart Association Houston Heart Ball.
Her contributions to medical sciences include opioid effects on evoked substance P release from primary sensory neurons, co-authoring the discovery of SUMO/Sentrin, and the cloning of Class H defect in Glycosylphosphatidylinositol Anchor. Recently she devoted majority of her time on onco-cardiology (cardio-oncology). With her cross-discipline expertise in epidemiology, evidence-based medicine, and basic research, she translated bench laboratory data to bedside clinical trials for prevention of doxorubicin-induced cardiotoxicity. This investigator initiated clinical trials received 3.48 million NIH RO1 award, HL 151993, 6/2020-5/2025.
Department of Pharmacology/Toxicology and Department of Internal Medicine
Harvard Medical School, Boston Children’s Hospital
Harvard Medical School, Boston Children’s Hospital
Research in Pain Medicine
Boston University Medical Center
George Washington University Medical Center
- Graduate School
Harvard Chan School of Public Health
Master of Science in Physiology
Master of Public Health in Epidemiology
- Medical School
National Taiwan University